[go: up one dir, main page]

WO2013168006A3 - Compositions et méthodes de traitement de la douleur locale - Google Patents

Compositions et méthodes de traitement de la douleur locale Download PDF

Info

Publication number
WO2013168006A3
WO2013168006A3 PCT/IB2013/051268 IB2013051268W WO2013168006A3 WO 2013168006 A3 WO2013168006 A3 WO 2013168006A3 IB 2013051268 W IB2013051268 W IB 2013051268W WO 2013168006 A3 WO2013168006 A3 WO 2013168006A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
treatment
neuralgia
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/051268
Other languages
English (en)
Other versions
WO2013168006A2 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Priority to CN201380030659.5A priority Critical patent/CN105612155A/zh
Priority to JP2015510898A priority patent/JP2016508956A/ja
Priority to EP13788349.2A priority patent/EP2882745A2/fr
Priority to CA2873138A priority patent/CA2873138A1/fr
Priority to SG11201407323WA priority patent/SG11201407323WA/en
Priority to AU2013257727A priority patent/AU2013257727B2/en
Publication of WO2013168006A2 publication Critical patent/WO2013168006A2/fr
Priority to ZA2014/08055A priority patent/ZA201408055B/en
Anticipated expiration legal-status Critical
Publication of WO2013168006A3 publication Critical patent/WO2013168006A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de formule I ou leurs sels pharmaceutiquement acceptables, ainsi que leurs formes polymorphes, leurs solvates, leurs énantiomères, leurs stéréoisomères et leurs hydrates. Elle concerne des compositions pharmaceutiques comprenant une quantité efficace de composés de formule I; et des méthodes de traitement de la douleur locale. Ces compositions peuvent être formulées pour administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, sous forme de sirop ou d'injection. Ces compositions peuvent être utilisées pour traitement par anesthésie par infiltration, anesthésie tronculaire, anesthésie péridurale ou anesthésie intrathécale. Elles peuvent être utilisées pour traiter la douleur, la douleur sévère, la douleur chronique, la douleur induite par la chimiothérapie, la douleur neuropathique, la névralgie post-herpétique, la névralgie, la maladie des motoneurones, la neuropathie diabétique, les lésions, la douleur postopératoire, l'arthrose, la polyarthrite rhumatoïde, la sclérose en plaques, les lésions de la moelle épinière, la migraine, la douleur neuropathique liée au VIH, la douleur cancéreuse, et la douleur du bas du dos.
PCT/IB2013/051268 2012-05-10 2013-02-16 Compositions et méthodes de traitement de la douleur locale Ceased WO2013168006A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201380030659.5A CN105612155A (zh) 2012-05-10 2013-02-16 治疗局部疼痛的组合物和方法
JP2015510898A JP2016508956A (ja) 2012-05-10 2013-02-16 局所疼痛の治療のための組成物と治療法
EP13788349.2A EP2882745A2 (fr) 2012-05-10 2013-02-16 Compositions et méthodes de traitement de la douleur locale
CA2873138A CA2873138A1 (fr) 2012-05-10 2013-02-16 Compositions et methodes de traitement de la douleur locale
SG11201407323WA SG11201407323WA (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
AU2013257727A AU2013257727B2 (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
ZA2014/08055A ZA201408055B (en) 2012-05-10 2014-11-04 Compositions and methods for the treatment of local pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1843CH2012 2012-05-10
IN1843/CHE/2012 2012-05-10

Publications (2)

Publication Number Publication Date
WO2013168006A2 WO2013168006A2 (fr) 2013-11-14
WO2013168006A3 true WO2013168006A3 (fr) 2016-09-01

Family

ID=54193695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/051268 Ceased WO2013168006A2 (fr) 2012-05-10 2013-02-16 Compositions et méthodes de traitement de la douleur locale

Country Status (8)

Country Link
EP (1) EP2882745A2 (fr)
JP (1) JP2016508956A (fr)
CN (1) CN105612155A (fr)
AU (1) AU2013257727B2 (fr)
CA (1) CA2873138A1 (fr)
SG (1) SG11201407323WA (fr)
WO (1) WO2013168006A2 (fr)
ZA (1) ZA201408055B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
CA2957010C (fr) 2008-09-26 2017-07-04 Relievant Medsystems, Inc. Systemes et procedes pour piloter un instrument a travers un os
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
US10390877B2 (en) 2011-12-30 2019-08-27 Relievant Medsystems, Inc. Systems and methods for treating back pain
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
CA3093398C (fr) 2012-11-05 2022-05-24 Relievant Medsystems, Inc. Systeme et methodes de creation de chemins incurves a travers un os et de modulation des nerfs au sein de l'os
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
KR102422382B1 (ko) * 2016-12-26 2023-01-25 셀릭스 바이오 프라이빗 리미티드 통증 치료를 위한 조성물
EP4027912B1 (fr) 2019-09-12 2024-12-18 Relievant Medsystems, Inc. Systèmes de modulation de tissu
AU2021306313A1 (en) 2020-07-10 2023-03-02 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
AU2021409967A1 (en) 2020-12-22 2023-08-03 Relievant Medsystems, Inc. Prediction of candidates for spinal neuromodulation
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1126435A (zh) * 1993-06-28 1996-07-10 阿斯特拉公司 罗哌卡因在具有最小运动神经阻断的止痛作用的药物制造中的应用
CN1279607A (zh) * 1997-11-19 2001-01-10 达尔文发现有限公司 麻醉制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187813A (zh) * 1995-05-01 1998-07-15 斯科舍集团有限公司 作为生物活性化合物的脂肪酸酯
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
US7560442B2 (en) * 2001-04-30 2009-07-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Pharmaceutically active uridine esters
WO2009061497A1 (fr) * 2007-11-07 2009-05-14 Svip5 Llc Libération lente de sels organiques d'anesthésique local pour un soulagement de la douleur
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2013024320A1 (fr) * 2011-08-17 2013-02-21 Mahesh Kandula Dérivés de 2,6-xylidine pour le traitement de la douleur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1126435A (zh) * 1993-06-28 1996-07-10 阿斯特拉公司 罗哌卡因在具有最小运动神经阻断的止痛作用的药物制造中的应用
CN1279607A (zh) * 1997-11-19 2001-01-10 达尔文发现有限公司 麻醉制剂

Also Published As

Publication number Publication date
AU2013257727A1 (en) 2014-11-27
WO2013168006A2 (fr) 2013-11-14
JP2016508956A (ja) 2016-03-24
EP2882745A2 (fr) 2015-06-17
ZA201408055B (en) 2016-03-30
CN105612155A (zh) 2016-05-25
CA2873138A1 (fr) 2013-11-14
AU2013257727B2 (en) 2016-04-28
SG11201407323WA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
WO2013168006A3 (fr) Compositions et méthodes de traitement de la douleur locale
WO2013175376A3 (fr) Compositions et méthodes de traitement de la douleur locale
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
WO2014031438A3 (fr) Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
PH12016500573A1 (en) Compound having somatostatin agonistic activity and pharmaceutical uses thereof
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2014087307A3 (fr) Compositions et procédés pour le traitement du syndrome métabolique et du diabète
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
WO2013175359A3 (fr) Compositions et méthodes pour le traitement de la sclérose en plaques
WO2014087323A3 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2014006529A3 (fr) Compositions et méthodes de traitement de la douleur modérée à aiguë
WO2013168004A3 (fr) Compositions et méthodes de traitement de la douleur fibromyalgique
WO2020075023A3 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EA033083B1 (ru) Циклические соединения
WO2013167989A3 (fr) Compositions et méthodes de traitement de troubles neurologiques
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2014097137A3 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
WO2014106804A3 (fr) Compositions et procédés de traitement du syndrome métabolique et du diabète
WO2014068506A3 (fr) Compositions et procédés pour le traitement de maladies autoimmunes
WO2014068459A3 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques
WO2013175344A3 (fr) Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
WO2015028976A3 (fr) Composés et méthodes de traitement de maladies inflammatoires
WO2013168005A3 (fr) Compositions et méthodes de traitement du syndrome des jambes sans repos et de la fibromyalgie
WO2014122621A3 (fr) Compositions et procédés pour le traitement d'états métaboliques et de maladies neuromusculaires
WO2014068461A3 (fr) Compositions et méthodes de traitement d'une inflammation aiguë

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2873138

Country of ref document: CA

Ref document number: 2015510898

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013788349

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013257727

Country of ref document: AU

Date of ref document: 20130216

Kind code of ref document: A